Pfizer amps up push into obesity treatments with $4.9B deal with Metasera
PositiveU.S News

Pfizer is making a significant move in the obesity treatment market by acquiring Metasera for $4.9 billion, just five months after halting its own obesity drug development. This acquisition highlights Pfizer's commitment to addressing obesity, a growing health concern worldwide, and positions the company to leverage Metasera's expertise and innovations in this field.
— Curated by the World Pulse Now AI Editorial System